Stewart Fisher - Aug 30, 2023 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Scientific Officer
Signature: /s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol: CCCC
Transactions as of: Aug 30, 2023
Transactions value $: -$1,937
Form type: 4
Date filed: 8/31/2023, 04:10 PM
Previous filing: Feb 15, 2023
Next filing: Sep 19, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Options Exercise		+2.25K	+2.2%		105K	Aug 30, 2023	Direct	F1
transaction	CCCC	Common Stock	Tax liability	-$1.94K	-661	-0.63%	$2.93	104K	Aug 30, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Performance Restricted Stock Units	Options Exercise	$0	-2.25K	-12%	$0.00	16.5K	Aug 30, 2023	Common Stock	2.25K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
F2	Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.